EP1244356A4 - COMPOSITIONS AND METHODS RELATING TO NUCLEOSIDES-L, NUCLEOTIDES-L AND THEIR ANALOGS - Google Patents

COMPOSITIONS AND METHODS RELATING TO NUCLEOSIDES-L, NUCLEOTIDES-L AND THEIR ANALOGS

Info

Publication number
EP1244356A4
EP1244356A4 EP00988189A EP00988189A EP1244356A4 EP 1244356 A4 EP1244356 A4 EP 1244356A4 EP 00988189 A EP00988189 A EP 00988189A EP 00988189 A EP00988189 A EP 00988189A EP 1244356 A4 EP1244356 A4 EP 1244356A4
Authority
EP
European Patent Office
Prior art keywords
nucleosides
nucleotides
analogs
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00988189A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1244356A1 (en
Inventor
Johnson Lau
Zhi Hong
Robert Tam
Kanda Ramasamy
Chin-Chung Lin
Fuesun Zeytin
Ljubisa Rakic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant Pharmaceuticals International Inc USA
Original Assignee
ICN Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICN Pharmaceuticals Inc filed Critical ICN Pharmaceuticals Inc
Publication of EP1244356A1 publication Critical patent/EP1244356A1/en
Publication of EP1244356A4 publication Critical patent/EP1244356A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
EP00988189A 1999-12-23 2000-12-19 COMPOSITIONS AND METHODS RELATING TO NUCLEOSIDES-L, NUCLEOTIDES-L AND THEIR ANALOGS Withdrawn EP1244356A4 (en)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US17209799P 1999-12-23 1999-12-23
US172097P 1999-12-23
US17344699P 1999-12-29 1999-12-29
US173446P 1999-12-29
US17511100P 2000-01-06 2000-01-06
US175111P 2000-01-06
US19075800P 2000-03-20 2000-03-20
US190758P 2000-03-20
US22694700P 2000-08-22 2000-08-22
US22687500P 2000-08-22 2000-08-22
US226875P 2000-08-22
US23354800P 2000-09-19 2000-09-19
US23382100P 2000-09-19 2000-09-19
US23382300P 2000-09-19 2000-09-19
US23382200P 2000-09-19 2000-09-19
US233821P 2000-09-19
US233548P 2000-09-19
US233822P 2000-09-19
US233823P 2000-09-19
US23546500P 2000-09-26 2000-09-26
US235465P 2000-09-26
PCT/US2000/034605 WO2001045509A1 (en) 1999-12-23 2000-12-19 Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
US226947P 2009-07-20

Publications (2)

Publication Number Publication Date
EP1244356A1 EP1244356A1 (en) 2002-10-02
EP1244356A4 true EP1244356A4 (en) 2003-03-19

Family

ID=27582702

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00988189A Withdrawn EP1244356A4 (en) 1999-12-23 2000-12-19 COMPOSITIONS AND METHODS RELATING TO NUCLEOSIDES-L, NUCLEOTIDES-L AND THEIR ANALOGS

Country Status (20)

Country Link
EP (1) EP1244356A4 (ja)
JP (1) JP2003523957A (ja)
KR (1) KR20030032908A (ja)
CN (1) CN1420723A (ja)
AU (1) AU2442201A (ja)
BR (1) BR0016162A (ja)
CA (1) CA2384326A1 (ja)
CZ (1) CZ20022112A3 (ja)
HK (1) HK1049944A1 (ja)
HR (1) HRP20020485A2 (ja)
HU (1) HUP0300219A3 (ja)
IL (1) IL148514A0 (ja)
MX (1) MXPA02006251A (ja)
NO (1) NO20022969D0 (ja)
NZ (1) NZ517634A (ja)
PL (1) PL364927A1 (ja)
SI (1) SI20976A (ja)
SK (1) SK8612002A3 (ja)
WO (1) WO2001045509A1 (ja)
YU (1) YU47802A (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
CN1863812A (zh) 2003-09-11 2006-11-15 弗·哈夫曼-拉罗切有限公司 多晶型核苷化合物
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CN101511185A (zh) * 2006-09-11 2009-08-19 南方研究所 唑类核苷和作为rna和dna病毒聚合酶抑制剂的用途
CN102952104A (zh) * 2011-08-17 2013-03-06 黑龙江省松花江药业有限公司 一种呋喃类化合物
CN106061984A (zh) 2014-02-13 2016-10-26 配体药物公司 前药化合物及其用途
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
CN104387431A (zh) * 2014-10-24 2015-03-04 江南大学 一种高特异性的利巴韦林人工抗原的制备方法
EP3156050A1 (en) * 2015-10-16 2017-04-19 Universitat Autònoma De Barcelona New combination therapies for treating neurological damage
CA3087932A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
CN109528638B (zh) * 2018-12-20 2021-07-06 江西润泽药业有限公司 利巴韦林衍生物制剂及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
WO1987005807A1 (en) * 1986-03-27 1987-10-08 Harry Edward Gruber A method of increasing adenosine excretion
WO1992004381A1 (en) * 1990-09-11 1992-03-19 Scotgen Limited Novel antibodies for treatment and prevention of infection in animals and man
EP0707855A2 (en) * 1995-05-19 1996-04-24 Schering Corporation Combination therapy for chronic hepatitis C infection
WO1998016186A2 (en) * 1996-10-16 1998-04-23 Icn Pharmaceuticals, Inc. Monocyclic l-nucleosides, analogs and uses thereof
EP0956861A1 (en) * 1998-05-15 1999-11-17 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection
WO2000030656A1 (en) * 1998-11-20 2000-06-02 The Salk Institute For Biological Studies Neuron stimulation by ribavirin, and analogs thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981507A (en) * 1995-12-14 1999-11-09 Advanced Magnetics, Inc. Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
WO1987005807A1 (en) * 1986-03-27 1987-10-08 Harry Edward Gruber A method of increasing adenosine excretion
WO1992004381A1 (en) * 1990-09-11 1992-03-19 Scotgen Limited Novel antibodies for treatment and prevention of infection in animals and man
EP0707855A2 (en) * 1995-05-19 1996-04-24 Schering Corporation Combination therapy for chronic hepatitis C infection
WO1998016186A2 (en) * 1996-10-16 1998-04-23 Icn Pharmaceuticals, Inc. Monocyclic l-nucleosides, analogs and uses thereof
EP0956861A1 (en) * 1998-05-15 1999-11-17 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection
WO2000030656A1 (en) * 1998-11-20 2000-06-02 The Salk Institute For Biological Studies Neuron stimulation by ribavirin, and analogs thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GABRIELSEN, BJARNE ET AL: "Synthesis and antiviral evaluation of N-carboxamidine-substituted analogs of 1-.beta.-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride.", JOURNAL OF MEDICINAL CHEMISTRY (1992), 35(17), 3231-8, 1992, XP002227435 *
GIUSEPPINA DI STEFANO, CORRADO BUSI, ALESSANDRO MATTIOLI, LUIGI FIUME: "Selective Delivery to the Livre of Antiviral Nucleoside Analogs Coupled to a High Molecular Mass Lactosaminated Poly-L-Lysine and Administrated to Mice by Intramuscular Route", BIOCHEMICAL PHARMACOLOGY, vol. 49, no. 12, 1995, UK, pages 1769 - 1775, XP002227434 *
J. BALZARINI, C.K. LEE, P. HERDEWIJN, E. DE CLRECQ: "Mechanism of the potentiating effect of Ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficient virus", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 32, 1991, USA, pages 21509 - 21514, XP002227433 *
JAHRLING P B ET AL: "ENHANCED TREATMENT OF LASSA FEVER BY IMMUNE PLASMA COMBINED WITH RIBAVIRIN IN CYNOMOLGUS MONKEYS", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 149, no. 3, 1 March 1984 (1984-03-01), pages 420 - 427, XP002030799, ISSN: 0022-1899 *
ROBERTO FERNANDEZ-LARSSON, JEAN L. PATTERSON: "Ribavirin in an inhibitor of Human Immunodeficiency Virus Reverse Transcriptase", MOLECULAR PHARMACOLOGY, vol. 38, no. 6, 1990, USA, pages 766 - 770, XP009003959 *
See also references of WO0145509A1 *

Also Published As

Publication number Publication date
NZ517634A (en) 2004-06-25
EP1244356A1 (en) 2002-10-02
CZ20022112A3 (cs) 2003-05-14
YU47802A (sh) 2006-03-03
CA2384326A1 (en) 2001-06-28
BR0016162A (pt) 2002-08-13
AU2442201A (en) 2001-07-03
HUP0300219A2 (hu) 2003-06-28
WO2001045509A1 (en) 2001-06-28
JP2003523957A (ja) 2003-08-12
NO20022969L (no) 2002-06-20
PL364927A1 (en) 2004-12-27
HRP20020485A2 (en) 2005-10-31
CN1420723A (zh) 2003-05-28
NO20022969D0 (no) 2002-06-20
MXPA02006251A (es) 2003-01-28
HUP0300219A3 (en) 2005-07-28
SI20976A (sl) 2003-02-28
KR20030032908A (ko) 2003-04-26
HK1049944A1 (zh) 2003-06-06
SK8612002A3 (en) 2003-03-04
IL148514A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
IL138280A0 (en) 20-KETO-11β-ARYLSTERIODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
ZA200004956B (en) Vaccine composition.
EP1294432A4 (en) HEMATOCRIT SAMPLING SYSTEM
MXPA03004402A (es) Composicion mejorada de sucralosa y procedimiento para su preparacion.
HUP0100706A3 (en) Methods for improving seeds
HUP0202762A3 (en) Solid lipid compositions, process for their preparation and use thereof
HK1097466A1 (en) Buffered compositions for dialysis
HK1052702A1 (en) Method for the preparation of 5-carboxyphthalide.
IL130882A0 (en) Sorbent composition
IL148514A0 (en) Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
GB9905817D0 (en) Methods
GB9926161D0 (en) Methods
EP1277459A4 (en) PERMANENT SHAFT MEANS AND METHOD FOR PERMANENT SHAFT USING THIS
GB9801870D0 (en) Vaccine composition
GB9823835D0 (en) Component for vaccine
ZA200202778B (en) Compositions and methods for L-nucleosides, L-nucleotides, and their analogs.
GB0002873D0 (en) Sample preparation method
HUP0302821A2 (hu) Eljárás szubsztituált 5-amino-N-fenil-1,2,4-triazol-3-szulfonamid-származékok előállítására
HK1047138A1 (zh) Bryostatins，bryopyrans and polyketides：構成與方法
GB9914943D0 (en) Methods
HRPK20000420B1 (en) Purine l-nucleosides, analogs and uses thereof
HRPK20000422B1 (en) Purine l-nucleosides, analogs and uses thereof
GB9802879D0 (en) Vaccine composition
GB9806455D0 (en) Vaccine composition
GB9824509D0 (en) Expression methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020723

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 39/42 B

Ipc: 7A 61K 31/70 B

Ipc: 7A 01N 43/04 A

Ipc: 7C 07H 19/056 B

Ipc: 7C 07H 19/00 B

Ipc: 7C 07H 19/044 B

Ipc: 7C 07H 19/04 B

A4 Supplementary search report drawn up and despatched

Effective date: 20030205

17Q First examination report despatched

Effective date: 20050601

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050702

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1049944

Country of ref document: HK